Aligos Therapeutics Ratios (2020-2025) | ALGS

Ratios Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Profitability
EBT Margin (Quarter)
-3,036.15%-1,928.16%-2,146.91%-10,292.10%-1,383.20%-157.02%-16,368.57%-419.98%-836.21%-1,389.85%-5,020.03%494.82%-1,533.44%-2,488.58%13,868.49%-1,624.66%-4,248.45%-11,746.15%
EBIT Margin (Quarter)
-3,048.35%-1,913.59%-2,151.46%-10,340.05%-1,383.00%-163.10%-17,084.29%-445.76%-885.38%-1,294.03%-3,176.66%-2,489.54%-1,610.48%-623.12%-6,187.46%-1,924.04%-3,827.40%36,186.98%
EBITDA Margin (Quarter)
-3,045.38%-1,931.52%-2,155.04%-10,085.01%-1,394.90%-155.63%-16,326.43%-437.66%-837.56%-1,385.96%-5,033.43%478.70%-1,534.08%-2,493.21%13,853.38%-1,646.63%-4,251.28%-11,756.21%
Operating Margin (Quarter)
-3,048.35%-1,913.59%-2,151.46%-10,340.05%-1,383.00%-163.10%-17,084.29%-445.76%-885.38%-1,294.03%-3,176.66%-2,489.54%-1,610.48%-623.12%-6,187.46%-1,924.04%-3,827.40%36,186.98%
Net Margin (Quarter)
-3,041.10%-1,929.97%-2,155.11%-10,276.29%-1,385.26%-157.37%-16,396.43%-437.61%-837.56%-1,388.35%-5,023.49%477.00%-1,540.72%-2,489.39%13,854.66%-1,643.83%-4,256.01%-11,763.91%
FCF Margin (Quarter)
-3,308.02%-1,499.68%-1,656.80%-10,304.09%-814.82%-121.33%-15,995.71%-317.09%-944.10%-1,127.82%-3,277.52%-1,837.23%-1,608.08%-557.67%-6,723.15%-1,606.63%-3,285.43%-12,866.86%
Efficiency
Assets Average (Quarter)
249.92M223.21M237.47M249.22M222.92M196.50M173.30M155.38M134.22M113.93M95.99M118.69M139.71M118.36M98.62M79.26M110.40M142.70M122.23M99.15M
Equity Average (Quarter)
207.63M182.05M192.95M200.87M168.81M144.93M129.50M112.96M94.33M77.19M62.23M73.45M75.94M63.51M58.66M10.56M43.74M109.16M86.85M62.69M
Invested Capital (Quarter)
195.22M168.88M217.01M184.73M152.89M136.98M122.01M103.90M84.75M69.64M54.82M92.08M59.80M67.23M50.10M-28.97M116.44M101.87M71.83M53.55M
Asset Utilization Ratio (Quarter)
0.020.030.020.020.110.100.160.210.070.070.050.050.080.050.040.040.02
Leverage & Solvency
Equity Ratio (Quarter)
0.830.800.820.780.730.750.740.710.700.660.640.610.470.620.57-0.410.770.760.650.60
Valuation
Enterprise Value (Quarter)
-213.41M-190.65M-242.19M-186.98M-106.12M-159.34M-86.52M-81.45M-103.52M-90.87M-70.50M-135.80M-24.37M-143.96M-114.49M-37.10M-202.00M-123.01M-42.06M-77.91M
Return Ratios
Return on Sales (Quarter)
-0.30%-0.19%-0.22%-1.03%-0.14%-0.28%-0.38%-0.02%-1.64%-0.04%-0.08%-0.14%-0.50%0.05%-0.15%-0.25%1.39%-0.16%-0.43%-1.18%
Return on Capital Employed (Quarter)
-61.03%-74.98%-77.02%-79.05%-79.82%-80.97%-97.67%-115.35%-92.98%-71.38%-98.67%-121.79%-154.99%-94.43%-64.12%-86.52%-6.44%
Return on Invested Capital (Quarter)
-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.02%-0.08%-0.02%-0.01%-0.01%0.00%
Return on Assets (Quarter)
0.00%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.02%0.00%-0.01%-0.01%0.00%
Return on Equity (Quarter)
0.00%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.12%-0.01%-0.01%-0.01%0.00%